tbuckley/cabot-search huggingface dataset:
Eleventh Floor
Authors: Marc J. Straus
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).
Authors: Halle C. F. Moore, Joseph M. Unger, Kelly-Anne Phillips, Frances M. Boyle, Erika Hitre, David James Porter, Prudence A. Francis, Lori M. Minasian, Richard D. Gelber, Lori J. Goldstein, Henry Leonidas Gomez, Carlos Vallejos, Ann H. Partridge, Shaker R. Dakhil, Silvana Martino, William E. Barlow, Carol J. Fabian, Frank L. Meyskens, Gabriel N. Hortobagyi, Kathy S. Albain
Journal: Journal of Clinical Oncology (2014)

LBA505 Background: Premature ovarian failure (POF) is a common toxicity of CT. Risk depends on type and amount of CT, age, and perhaps ovarian cycling at the time of CT. POEMS is a SWOG-coordinated phase III randomized study to evaluate whether LHRH analog administration with CT for early-stage breast cancer (BC) would reduce POF. Methods: Premenopausal patients (PT) age <50 with stage I-IIIA ER/PR-negative BC to be treated with CT were randomized to receive standard cyclophosphamide-containing CT with or without monthly goserelin (GN) 3.6 mg SQ starting 1 week prior to the first CT dose. The primary endpoint is 2-year POF, defined as amenorrhea for the prior 6 months and post-menopausal FSH. Other endpoints include pregnancies and survival. Endpoints were analyzed in multivariable regression adjusting for stratification factors (age and CT regimen). Results: Between 2/04 and 5/11, 257 PT enrolled. Among 218 evaluable PT, 62% had complete primary endpoint data. Dropouts (n=83) were mostly due to deaths (n=14) or lack of FSH data. There was no strong evidence of informative missing data by arm according to stratification factors (p>.05). POF rates were 22% in the standard arm and 8% in the GN arm (OR=0.30, 95% CI: 0.10-0.87, p=.03 [unadjusted analysis]; OR=0.36, 95%CI: 0.11-1.14, p=0.08 [adjusted logistic regression analysis]). In a sensitivity analysis defining 2-year POF more liberally as either amenorrhea or elevated FSH, 45% in the standard arm and 20% in the GN arm had POF (OR=0.29, 95% CI: 0.12-0.70, p=.006). There were 13 pregnancies in the standard arm and 22 in the GN arm (OR=2.22, 95% CI: 1.00-4.92, p=.05). DFS and OS were better in the GN arm (Cox regression, including stage: HR=0.49, 95% CI: 0.24-0.97, p=.04; HR=0.43, 95% CI: 0.18-1.00, p=.05, respectively). Conclusions: LHRH analog administration with CT was associated with less POF and more pregnancies. In an exploratory analysis, GN use in premenopausal ER-negative BC was associated with improved DFS and OS. Clinical trial information: NCT00068601.
Clinical Experiences with Polythiazide in the Treatment of Hypertension
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 419: OLA1 Regulates GSK3β/eIF2-alpha Signaling Axis in Angiotensin II-treated Human Ventricular Cardiomyocytes
Authors: Prince Jeyebal, Zheng-Zheng Shi, Prasanna Krishnamurthy
Journal: Circulation Research (2017)

Pathological cardiac hypertrophy in response to stress or disease such as hypertension, myocardial infarction, valvular disease or neurohomonal dysregulation often result in heart failure. Cardiac hypertrophy is associated with changes in key molecular features including protein synthesis, sarcomeric organization, fibrogenesis, cell death and energy metabolism. OBG like ATPase 1 (OLA1) belongs to the translation factor-related (TRAFAC) class, Obg family, and YchF subfamily of P-loop GTPases that play a crucial role in the regulation of diverse cellular processes including protein translation, intracellular transport, signal transduction and growth. Recent study has shown that OLA1 functions as an intrinsic regulator in cellular stress responses, such as oxidative stress and heat shock. However, its role in cardiac hypertrophy is unknown so far. Here, we investigated the effect of OLA1 deficiency on angiotensin II (ANG II)-induced hypertrophic signaling response in immortalized human ventricular cardiomyocytes (hCM) and in heart tissue from OLA1 knockout mice. We observed that ANG II-induced increase in cardiomyocyte cell size was lower in OLA1 knockdown hCM cells as compared to control transfected cells. Interestingly, OLA1 knockdown inhibits the above effect and increases phosphorylation of GSK3β and eIF2α (inactive state). Furthermore, OLA1 homozygous knockout mice showed increase in phosphorylation of GSK3β. Taken together, these findings show that OLA1 deficiency decreases ANG II-induced hypertrophy signaling response in ventricular cardiomyocytes. This study provides the first evidence for the role of OLA1 in ANG II-induced hypertrophic response of human ventricular cardiomyocytes.
Der Künstliche Pneumothorax.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PARASITIC HEMOPTYSIS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HIV prevalence data mount, patterns seen emerging by end of this year
Authors: M. F. Goldsmith
Journal: JAMA (1988)

HOW DEEP an incursion has human immunodeficiency virus (HIV) made into the population of the United States? Are 1.5 million (estimated) seropositive persons really infected now and likely sooner or later to come down with acquired immunodeficiency syndrome (AIDS)? Could the actual number be much lower—or much higher? The Centers for Disease Control (CDC), Atlanta, is trying to answer these tough questions. Next month, a study that may point the way toward getting part of the answer will begin in a medium-sized city in the mid-Atlantic states. Gary Noble, MD, the CDC's deputy director for AIDS, says the way is being carefully prepared for this initial pilot study, which aims to gather from 300 to 500 households information that will help determine the feasibility of conducting a full-scale National Household Seroprevalence Survey. <h3>Early Setback</h3> This blood sample and interview survey, planned to be an important part of the Comprehensive Family
Transactions of the Medical and Chirurgical Faculty of the State of Maryland.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
National Committee for Mental Hygiene.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NCCN NewsNCCN to Host 13th Annual Congress: Hematologic Malignancies September 2018 in NYCNCCN Convenes Summit on Providing High-Quality Cancer Care in an Evolving Policy and Tech LandscapeNCCN Seeking Poster Presentations from Top Oncology Researchers
Authors: Ranjana Advani, Andrew Zelenetz
Journal: Journal of the National Comprehensive Cancer Network (2018)

World-renowned experts in the management of hematologic malignancies will present the latest treatment advances, updates to the standard of care as recommended in the NCCN Guidelines, and unique and challenging patient cases at the
Changes in Voice During Treatment with Anabolic Steroids
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Data Inaccuracies in Text and Tables
Authors: Karina Davidson
Journal: JAMA (2020)

Joseph Moscola, PA, MBA; Grace Sembajwe, DSc, MSc, CIH; Mark Jarrett, MD, MBA, MS; Bruce Farber, MD; Tylis Chang, MD; Thomas McGinn, MD, MPH; Karina W. Davidson, PhD, MASc; Northwell Health COVID-19 Research Consortium
Efficacy and tolerance of obeticholic acid in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid in real life: interim analysis of the OCARELIFE study
Authors: Leroy Vincent, Christophe Corpechot, Jérôme Dumortier, Laurent Alric, Dominique Larrey, Sebastien Dharancy, Olivier Chazouillères, Alexandra Heurgue-berlot, Francois Boer, Aldo Trylesinski
Journal: Journal of Hepatology (2020)
Pharmacokinetics and Metabolism of Benzene in Zymbal Gland and Other Key Target Tissues after Oral Administration in Rats
Authors: Lawrence K. Low, J. Ralph Meeks, Kenneth J. Norris, Myron A. Mehlman, Carl R. Mackerer
Journal: Environmental Health Perspectives (1989)

Solid tumors have been reported in the Zymbal gland, oral and nasal cavities, and mammary gland of Sprague-Dawley rats following chronic oral administration of benzene. The cause for the specificity of such lesions remains unclear, but it is possible that tissue-specific metabolism or pharmacokinetics of benzene is responsible. Metabolism and pharmacokinetic studies were carried out in our laboratory with 14C-benzene at oral doses of 0.15 to 500 mg/kg to ascertain tissue retention, metabolite profile, and elimination kinetics in target and nontarget organs and in blood. Findings from those studies indicate the following: a) the Zymbal gland is not a sink or a site of accumulation for benzene or its metabolites even after a single high dose (500 mg/kg) or after repeated oral administration; b) the metabolite profile is quantitatively different in target tissues (e.g., Zymbal gland, nasal cavity), nontarget tissues and blood; and (c) pharmacokinetic studies show that the elimination of radioactivity from the Zymbal gland is biphasic.
Training the resident to meet the detail men
Authors: R. P. Ferguson
Journal: JAMA (1989)

<h3>To the Editor.—</h3> Dr Shaughnessy<sup>1</sup>pointed out that the continuous exposure of residents in training to medical advertising was likely to influence their prescribing habits. Most physicians complete training unable to evaluate data on new pharmaceuticals critically, data that typically reaches the physician through advertising or via a potentially subjective presentation by a medical service representative—the "detail man." Physicians who are new in practice usually are unprepared to deal with the ethical conflicts that can develop through physician "incentive" programs, which apparently are becoming more imaginative and played at higher stakes.<sup>2</sup> In September 1988, we initiated a seminar series as part of the developing University of Connecticut primary care residency program. A major part of our first seminar was devoted to pharmaceutical marketing strategies and the interaction of the physician with the medical service representative. Participants included primary care faculty at the University of Connecticut—affiliated Mount Sinai and New
Time and the Physician: The Autobiography of Lewellys F. Barker
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Schools in Canada
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Author's reply
Authors: M J Fritzler
Journal: Annals of the Rheumatic Diseases (1994)

Whereas IL-Ira can completely prevent the latter process,' blocking activation of the mature osteoclast requires simultaneous inhibition of TNF and IL-1.' It would therefore be logical to contemplate clinical trials in RA, inhibiting both of these cytokines and observing the effect on RA related osteoporosis as an end point.
Errors in the guaiac test for occult blood
Authors: H. D. Markman
Journal: JAMA (1967)

<h3>To the Editor:—</h3> During a lecture and clinical demonstration, I performed a guaiac test for occult blood on a stool specimen that appeared tarry, and obtained a negative reaction. In order to illustrate how a positive reaction should appear, I repeated the test with a specimen containing fresh blood. To my discomfiture, this too, produced a negative result. This communication is written to call attention to some of the causes of such false reactions. As is well known, the guaiac test is usually performed by smearing a small quantity of stool on a piece of filter paper. Two drops of each of the following reagents are added in succession and mixed with the stool: glacial acetic acid, saturated alcoholic solution of gum guaiac, and 3% hydrogen peroxide. The presence of occult blood is indicated by the appearance of a deep blue color within one minute.<sup>1</sup> What is less known,
Or in the heart or in the head.
Journal: BMJ (1976)

nothing to do with transplant surgery or with euthanasia: it is a straight clinical assessment that the patient is dead though his heart is still beating.The clinical decision is, however, a weighty one and for that reason the code of practice agreed by the Conference of Royal Colleges and Faculties of the United Kingdom is welcome (see p 1187).It sets out clear guidelines for the diagnosis of death, including a recommendation that the decision to withdraw artificial support should be taken by two doctors.There is a consensus of medical opinion throughout the western world on the diagnosis of brain death.Perhaps we may now see an end to uninformed comment on the topic.